FAST STATS
Vizient, Inc. released its July 2019 Drug Price Forecast projecting health systems, including inpatient and non-acute environments.
“This Drug Price Forecast predicts continued growth of pharmaceutical costs that far exceeds both infl ation and wage growth, making healthcare less affordable,” said Dan Kistner, Group Senior Vice President, Pharmacy Solutions, Vizient.
Here's what the GPO’s research indicates: 4.57
percent projected increase would be made for pharmaceutical purchases from Jan. 1,
2020 to Dec. 31, 2020. And since hospitals are increasingly offering services in the non-acute setting -- outpatient infusions, home infusion, and specialty pharmacy services – spend
profi les now include new and specialized FDA- approved medications, which are the costliest.
22 biosimilars were approved by FDA as of
July 2019, with seven available in the market. Additionally, the most relevant patents protecting rituximab, bevacizumab and trastuzumab will expire during the third quarter of 2019.
$10 BILLION
is spent across the U.S. healthcare system for biosimilars, with specialty drug price infl ations predicted to increase by 4.23 percent, resulting in the need for providers to increase their drug budgets in the coming year.
$359 MILLION
is the total cost of increased labor (based on the responses from approximately 365 hospitals and health systems) needed to manage drug shortages. New entrants into the market are not anticipated to have a large
effect on supply and prices are expected to rise steadily in 2020 for immunoglobulin products, while albumin, for which supply remains abundant, will likely see price reductions.
8-PLUS MILLION
labor hours are dedicated to managing drug shortages in U.S. hospitals. Supply challenges in the Immune globulin intravenous (IgIV)
market will continue and prices are expected to steadily rise. Vizient anticipates that
supply of IgIV will continue to be limited for the remainder of 2019 and into the fi rst half of 2020 as manufacturers work to increase production to meet demand.
Source: Viient “uly 201 rug rice orecast” 6
NEWSWIRE
FDA aims to improve drug supply chain integrity, patient safety The ood and rug Administration an- nounced that it plans to inactivate listing records in its database that have not been recently updated or certifi ed, as reuired by regulation, or that include an establishment with an expired registration. The agency has found that tens of thou-
sands of drug listing records have not been updated or certifi ed in the past year, and are therefore not in compliance with federal regulations, which can slow down surveil- lance operations for certain A programs. Many of these listings are for products
that are no longer being mareted in the nited tates, but for which the manu- facturer never updated the listing. uch outdated listings nonetheless compromise the integrity of the As database and the As ability to mae accurate and timely decisions to protect public health. A regulations reuire all drug manu-
facturers to register their manufacturing facilities and provide a list of all drugs they are actively manufacturing for com- mercial distribution in the .. as one of the safeguards protecting our drug supply chain, said A Acting ommissioner ed harpless, M in the statement. t is vital that the A database accurately de- scribes drugs currently available to patients in the .. so the A can more uicly respond to and assess drug uality issues, adverse event reports, inspections, recalls, shortages and other supply chain security issues. A says no public health issues have resulted yet. isting records that are up to date are publicly available in the As ational rug ode irectory. rugs with inacti- vated listing records may not be legally mareted or imported in the .. omestic and foreign establishments that
manufacture, repac or re-label drugs in the .. are reuired to register with the A. This information helps the A main-
tain a catalog of all drugs in commercial distribution in the .. rug manufactur- ers must provide registration and listing information or updates regarding any drug listing data changes twice each year, in une and ecember, or must certify that there have been no changes to previously submitted drug listing data by ecember each year. The agency urges companies to update inaccurate active drug listing submissions as soon as possible, as inactive listings as of eptember , will be removed from the database. Additional updating reuirements and deadlines are available in the federal register notice.
September 2019 • HEALTHCARE PURCHASING NEWS •
hpnonline.com
Primary care clinic staffi ng mix should depend on patient needs and payment models In a new analysis of primary care clinics, remier nc. identifi ed wide variation in staffi ng model composition, performance and costs. Premier also found that skill mix is not necessarily a predictor of provider productivity. The analysis and opportuni- ties for improvement were published in Premier’s latest Ready, Risk, Reward white paper titled ptimiing rimary are Model esign to mprove erformance. The says it used its database of
detailed physician practice information, which includes more than , clini- cians, and benchmared data from family medicine and primary care practices. The analysis found that medical assistant MA-only staffi ng models may be the most cost-effective option for prac- tices that are fee-for-service revenue based. rimary care is one of the highest pri-
orities for health systems as they move to value-based care and payment models, said hris medley, Vice resident of hysician nterprise ervices, remier. owever, many primary care clinics are still operating under fee-for-service and lac the insights necessary to effectively adjust their operating models as they tran- sition to value. There was no correlation to high-
er levels of productivity in practices with a richer skill mix. It also found that practices operating in the upper range of productivity were more liely to have more support staff per provider. pecifi cally percent of family medicine and pri- mary care clinics in the analysis used a MA-only model
percent were staffed with a combi- nation of registered nurses s or licensed practical nurses s along with MAs
percent were staffed with s, MAs and s linics with MA-only models and com- parable staff were just as liely to achieve top uartile performance as higher sill mix models with s. urthermore, MA- only staffi ng models were almost half the cost of higher sill mix models i.e., , and MA, with no discernable differ- ences in productivity or output. igher sill mix models that are not
using their staff to better coordinate and manage care may be contributing to a higher cost of care, said medley. As the industry moves toward value, partici- pating in ris-based models will become a more viable option for many to ensure fi nancial success. roviders will need to
Page 8
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56